Introduction of potential genes and signal pathways related to cisplatin resistance in the A2780 cell line based on Bioinformatics analysis. by Hadi Alizadeh (20854757)

Subjects:

Viability and drug resistance of A2780 cells following AGPAT3 overexpression. by Hadi Alizadeh (20854757)

Subjects:

Effect of AGPAT3 downregulation on the mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects:

Effect of AGPAT3 overexpression on mTORC1 signaling pathway. by Hadi Alizadeh (20854757)

Subjects:

Characterization of cisplatin resistance phenotype in A2780 and A2780cp cells. by Hadi Alizadeh (20854757)

Subjects:

The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties. by Wangyong Shin (6793040)

Subjects:

The decrease in embryonic survival after stress coincides with a decrease in oocyte and embryo size. by Sarah Fausett (11812818)

Loss of EBNA3C-CtBP binding decreases p300 occupancy at promoters of EBNA3C induced genes. by Makoto Ohashi (104612)

N2142A mutation could reduce mortality rate and severity of symptoms by decreasing viral loads in limb muscle and spinal cord. by Xue Li (285380)

Subjects:

HVR1-swap compensatory E1/E2 substitutions typically decrease virus entry dependency on SR-BI. by Christina Holmboe Olesen (11154333)

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Phosphorylation of PFK2 is decreased in cardiomyocytes cultured in the absence of insulin and with diabetes. by Craig A. Eyster (9262632)

“…(B) Quantitation of mean fluorescence intensity (MFI) for pPFK2 are presented as whisker plots that encompass data from at least 18 cells, as detailed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0231806#pone.0231806.g001" target="_blank">Fig 1</a> (n = 3 biological replicates, and at least 6 cells per experiment). (*) IBMX or Isoproterenol treatment causes a significant increase (<i>p</i> < .001) compared to untreated WT cells; (†) Each WT (-ins) condition is significantly decreased (<i>p</i> < .001) compared to WT (+ins); (‡) all Akita conditions are significantly decreased (<i>p</i> < .001) compared to comparable WT conditions. …”

Excessive LF4A kinase activity shortens cilia and decreases IFT. by Yu-Yang Jiang (7036916)

A typical GABA-MRS spectrum, where peaks of GABA, NAA, and combined glutamate and glutamine (Glx) are measured. by Hiroyuki Matsuta (13250169)

Subjects:

eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs. by Dong Ma (584680)

Subjects:

Decreased muscle size and bone mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

Hematopoietic-restricted loss of Zeb1 decreases hematopoietic colony formation potential and ability to compete with wt HSPCs for contribution to all hematopoietic lineages. by Jueqiong Wang (11467505)

“…<p><b>(A)</b> HSPCs isolated from Vav-iCre; <i>Zeb1</i>^fl/fl fetal livers show decreased numbers of colonies in methylcellulose-based colony assays (first) that further decreases upon secondary replating (second) compared to Cre negative controls. …”

Conditions that ablate cytonemes decrease signaling, reduce myoblast and tumor growth. by Sol Fereres (664350)

Simulated effects of increased pCREB combined with decreased pCaMKIIα on time courses of molecular pathways and synaptic weight W after IA training. by Yili Zhang (540283)

“…(B) Example of dynamics of BDNF protein/mRNA (B1-2), C/EBPβ protein (B3), pCREB (B4), pCaMKIIα (B5), Sin3a binding (B6), MeCP2 binding (B7), HDAC2 binding (B8), and W (B9), with the standard parameter values in <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1010239#pcbi.1010239.t001" target="_blank">Table 1</a> (black dashed) or with <i>k</i>_{<i>basalp_creb</i>} increased by ~50% and <i>k</i>_{<i>basalp_CaMKII</i>} decreased by ~50% from control combined with higher binding levels of MeCP2, Sin3a and HDAC2 (blue) to simulate IA conditioning in infant rats. …”

M344 decreases orthotopic pancreatic tumor growth when used as a treatment alone or in combination with gemcitabine. by Shelby M. Knoche (13833807)